DENTSPLY SIRONA (XRAY) announced that the company plans to refocus the Byte business model around treatments that include expanded in-person dentist oversight. The Company is evaluating the go-to-market business and economic model and expects to leverage collaborative direct-to-consumer demand generation with dentists using Byte core competencies, expand digital customer journey management across the aligner portfolio, and utilize Byte skillsets to further enhance customer service and marketing across the Company. In connection with this review, Dentsply Sirona is not reinstating the at-home Byte Aligner Systems and Impression Kits but will continue to provide support for non-contraindicated Byte Aligner patients currently undergoing treatment. Dentsply Sirona will continue to work with regulatory authorities and obtain any necessary clearances prior to any market launch.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona downgraded to In Line from Outperform at Evercore ISI
- Dentsply Sirona price target lowered to $23 from $30 at Morgan Stanley
- Shareholder Alert for Dentsply Sirona, Inc. (NASDAQ:XRAY)
- GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls
- Dentsply Sirona initiated with a Neutral at Mizuho